Ilic D, et al. – This systematic review and meta-analysis examined the safety and the efficacy of prostate-specific antigen (PSA) testing for prostate cancer screening. This study included five randomized, controlled trials, which enrolled 721,718 men. Screening for prostate cancer may result in a small absolute benefit in disease-specific mortality over 10 years but does not improve overall mortality. Findings indicated that physicians and patients considering PSA-based screening need to weigh these benefits against the potential short- and long-term harms of screening, including complications from biopsies and subsequent treatment, and the risk of overdiagnosis and overtreatment.